A new way to calm eczema flares—for good.

No more whack-a-mole with eczema flares.

For people with atopic dermatitis (AD), the struggle never stops. Constant itch, recurring flares, and persistent skin irritation remain top patient concerns. Despite countless treatments, there is still no option that provides safe, tolerable, and lasting relief for mild-to-moderate AD.

S. aureus is implicated in 70–83% of AD flares, but its role remains under-addressed by modern therapeutics.

Just before an AD flare, S. aureus surges, releasing proteases and toxins that weaken the skin barrier and elicit the immune response. Targeting the microbial drivers of AD opens the door to a new class of treatments that could work alongside immunosuppressants and emollients for more comprehensive, lasting relief.

ENS-002 pacifies S. aureus virulence as a potential therapeutic for atopic dermatitis.

ENS-002, or “Ensemble No.2,” is a trio of topical bacteria that neutralizes S. aureus virulence on the skin. Designed for long-term relief, ENS-002 aims to prevent AD flares without the side effects of traditional treatments—making it suitable for all ages and severities.

Concerto is currently conducting a Phase 1b trial to evaluate ENS-002’s safety and mechanism of action in people with atopic dermatitis. Interested in participating in the clinical trial? Learn more about enrolling.

To expand to additional skin applications, Concerto performed kChip screens against 10 major skin targets.

Through >40M kChip data points, Concerto has learned how critical microbes implicated in skin health and disease (C. acnes, S. epidermidis, etc.) are influenced by combinations of skin microbes. This dataset serves as a goldmine for hit generation, fueling Concerto’s pipeline and strengthening a foundation for partnering around novel dermatology assets.